About this role
Jeff Albers, JD
Chairman
Jeff Albers has more than 25 years’ experience working in the biopharmaceutical industry, contributing to bringing new medicines to patients with cancer and rare diseases. He is currently Chairman at Blueprint Medicines, where he previously held the position of Chief Executive Officer from 2014 to 2022. As CEO at Blueprint Medicines, a research-stage company, he led the company through an Initial Public Offering (IPO) and helped the company evolve into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline.
Jeff is currently on the board of directors of Kymera Therapeutics and Magenta Therapeutics and serves on the board of advisors for Life Sciences Cares.
During his career, Jeff has also served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, Jeff held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), including Vice President of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo.
He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.